Home › Trial NCT06970782
Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure
- Trial IDNCT06970782
- StatusNot Yet Recruiting
- PhasePhase 3
- Study typeInterventional
- SponsorAvistone Biotechnology Co., Ltd.
- Enrollment278
- Start date2025-05-15
- ConditionsNon-Small-Cell Lung Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.